Back to Journals » Vascular Health and Risk Management » Volume 12
Review
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
42,136 | Dovepress* | 14,461+ | 3,083 | 17,544 | |
PubMed Central* | 27,675 | 5,272 | 32,947 | ||
Totals | 42,136 | 8,355 | 50,491 | ||
*Since 17 February 2016 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
30 | 0 | 0 | 0 | 14 | 16 |
View citations on PubMed and Google Scholar